Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Relevance and comparability of global laboratory molecular detection of influenza by the U.S. Department of War, 2025-2026.

Created on 13 Oct 2026

Authors

Dara A Russell, Marissa K Hetrich, Kathleen E Creppage, M Shayne Gallaway

Published in

MSMR. Volume 33. Issue 9. Pages 30-36. Sep 20, 2026. Epub Sep 20, 2026.

Abstract

The U.S. Department of War (DOW)'s Global Emerging Infections Surveillance (GEIS) program conducts influenza surveillance within all geographic combatant commands to enhance U.S. force health protection and military readiness. This report compares laboratory-confirmed influenza data from the GEIS network with the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS) from late 2025 through early 2026. Findings from the most recent 2025-2026 respiratory season show that while influenza trends were largely similar, with influenza A/H3N2 predominating, significant differences in percent positivity or subtype ratios emerged in Asia, East Africa, and South America. These discrepancies highlight the unique value of GEIS data, which fills critical surveillance gaps in strategic regions. This targeted surveillance provides crucial insights for mitigating infection risk to U.S. service members, informs annual vaccine strain selection, and ensures an early warning capability for emerging respiratory threats, directly supporting the readiness of the force.

PMID:
42865759
Bibliographic data and abstract were imported from PubMed on 13 Oct 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement